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The term “Non-clear cell Renal Cell Carcinoma (nccRCC)’’ 
recognized a large series of renal tumours characterized of 
a specific genomic and morphological signature. Compared 
to clear cell renal cell carcinoma (ccRCC), these tumours 
are uncommon diagnoses with an overall incidence around 
20–25% of primary kidney tumours) (1).
The last pathological  classif ication of nccRCC 
(2016-World Health Organization) defines over a dozen of 
different histopathological entities (2). 
Papillary renal cell carcinoma (pRCC) and Chromophobe 
Renal Cell Carcinoma (chRCC) are the most frequent 
subtypes (10–15% Prcc, 4–5% chRCC) of nccRCC while 
medullary, translocation and collecting duct RCC represent 
an infrequent diagnosis. 
Although several efforts have been made to improve 
therapeutic options of patients with metastatic nccRCC, 
the clinical outcomes achieved resulted significantly worse 
when compared to those observed in metastatic ccRCC (1). 
The main explication is due to the exclusion of nccRCC 
patients from clinical and treatment trials. Therefore, the 
majority of evidences regarding treatment management 
of these tumours derived from retrospective analysis 
and expanded access programs. Historically, metastatic 
nccRCCs have been treated in the same way of metastatic 
ccRCCs and very few interventional studies have been 
developed specifically for nccRCCs (Table 1). 
This negative trend has been changed in last years mainly 
thanks to an increased knowledge of molecular and genomic 
behaviours of each tumour. Results provided by genomic 
analysis and The Cancer Genomic Atlas (TCGA) have 
significantly characterized this heterogeneous spectrum of 
tumours (3-6). In particular:
	Papillary renal cell carcinoma (pRCC) is a disease, 
which involve tumours associated to indolent 
course and favourable clinical outcomes (type I) and 
tumours associated to clinical aggressiveness and 
poor prognosis (type II). Alteration of the MET 
genes can be observed in over 80% of type I and 
about 45% of type II pRCC. These two tumours 
also shared often alteration in SETD2 (chromatin 
remodelling gene) and sometimes express alteration 
of EGFR gene. 9p loss, and CpG island methylator 
phenotype are two genomic findings associated to 
poor prognosis and are generally observed in type II 
pRCC (3-6). 
	Chromophobe Renal Cell Carcinoma (ChRCC) is 
often associated to TP53 mutation (32%), mTOR 
(23%) and PTEN (9%). Of note chromosome loss 
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and alteration in mitochondrial DNA, number 
and morphology could often been observed in this 
histotype suggesting that metabolic alteration occur 
very frequently (3-6).
	Translocation renal cell carcinoma (TRCC) is 
a specific tumour occurring generally in young 
patients. The most commonly alteration involves 
TFE3  gene (Xp11.2) which encodes protein 
modulating transcription process. TFEB-amplified 
RCC is recently described entities and is associated 
to very aggressive disease. Of note, no alteration of 
VHL could be found in TRCC (3-6).
	Collecting duct carcinoma (CDC) is a tumour 
associated to metabolic shift and presents a strongly 
immunogenic behaviour due to the up-regulation of 
different genes involved in lymphocyte activity (3-6).
Table 1 Summary tables of prospective/retrospective series in nccRCC 
Study name or 
first author
Drug/s N
Line of 
treatment
Type of study ORR PFS OS
ASPEN Everolimus 
vs. Sunitinib
108 First Prospective Everolimus =8%; 
Sunitinib =18%
Everolimus =5.6 months 
(5.5–60); Sunitinib =8.3 
(5.8–11.4)
Everolimus =13.2 
(9.7–37.9); Sunitinib 
=31.5 (14.8–NA)
ESPN Everolimus 
vs. Sunitinib
68 First/Second Prospective Everolimus =3%; 
Sunitinib =11%
Everolimus =4.1 months 
(2.7–10.5); Sunitinib =6.1 
(4.2–9.4)
Everolimus =14.9 
(8.0–23.4); Sunitinib 
=16.2 (14.2–NA)
RECORD 3 Everolimus 
vs. Sunitinib
66 First/Second Prospective NR Everolimus =5.1 months 
(2.6–7.9); Sunitinib =7.2 
(5.4–13.8)
NR
NCT00726323 Foretinib 74 First/Second Prospective 13.5% 9.3 months (6.9–12.9) Not reached
NCT02127710 Savolitinib 109 First Prospective 18% (in MET +) MET+ =6.2 months (4.1–7.0) NR
ARCC 
NCT00065468
INF vs. 
Temsirolimus
73 First Prospective INF =12%; 
Temsirolimus =12%
INF=1.8 (1.6–2.1); 
Temsirolimus=7.0 (3.9–8.9)
INF =4.3 (3.2–7.3); 
Temsirolimus =11.6 
(8.9–13)
RAPTOR Everolimus 88 First Prospective 1% pRCC type I =7.9 (2.1–11); 
pRCC type II =5.1 (3.3–5.5)
pRCC type I =28.0 
(7.6–NA); pRCC 
type II =24.2 
(15.8–32.8)
SUPAP Sunitinib 61 First Prospective NR pRCC type I =6.6 (2.8–14.8); 
pRCC type II =5.5 (3.8–7.1)
pRCC type I =17.8 
(5.7–26.1); pRCC 
type II =12.4 
(8.4–14.3)
NCT01798446 Axitinib 40 Second/
Third
Prospective 37.5% 7.4 months (5.2–9.5) 12.1 months 
(6.4–17.7)
Martínez 
Chanzá N
Cabozantinib 112 All Retrospective 27% Time to treatment failure:  
6.7 months (5.5–8.6)
12 months OS 51% 
(39–62%)
Pisciandaro M Cabozantinib 17 All Retrospective 35% 7.83 months (0.4–13.4) 12 months OS: 
60%
Matthew T. 
Campbell
Cabozantinib 30 All Retrospective 14.3% 8.6 months (6.1–14.7) 25.4 months 
(11.4–28.8)
De Giorgi U. Nivolumab 35 All Retrospective 19.3% NR NR
Koshkin  
Vadim S
Nivolumab 41 All Retrospective 20% 3.5 months Not reached
NR, not reported; OS, overall survival; PFS, progression free survival; ORR, objective response rate; N, number of patients.
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	Renal medullary carcinoma (RMC) is a very 
uncommon diagnosis and alteration of genes 
regulat ing chromatin-remodel l ing complex 
(SMARCB1/INI1) have been described (3-7).
Molecular characterization of nccRCC has led to 
understand that these tumours have a very complex panel 
of altered genes and thus the development of new drugs for 
metastatic disease should be tailored for a specific genomic 
alterations or selected tumour histology. 
Tailored trials are currently ongoing (Table 2). The 
MET inhibitor savolitinib has shown promising activity 
in pRCC with MET-driven mutations and a phase III trial 
(SAVOIR) comparing savolitinib to sunitinib in patients 
with MET-driven pRCC tumours is currently ongoing. 
The randomized phase II trial PAPMET is currently 
comparing a VEGFR, MET or VEGFR/MET (sunitinib, 
cabozantinib, Crizotinib, Volitinib) inhibition strategies 
in patients with pRCC unselected for MET. Other 
compounds are represented by PARP inhibitors in patients 
with hereditary leiomyomatosis and renal cell carcinoma 
syndrome; CDK4/6 inhibitors in tumors with CDKN2A 
loss and EZH2 inhibitors in tumours with INI1 (chromatin 
remodelling pathways mutations).
Despite tailored trials are surely a promising approach 
for the evaluation of new compounds in nccRCC it should 
not be forgotten that the results provided by these studies 
may require several years due to the low incidence of these 
tumours and thus the slow accrual of patients. 
A revolution in the management of metastatic ccRCC is 
currently in progress and several new compounds have been 
approved in clinical practice (8). 
As observed in “target therapy era” also recently 
registration clinical trials have excluded nccRCC from 
population on study. Therefore, once again our efforts 
should be spent to translate and evaluate the activity of 
these new compounds in patients with nccRCC. 
Expanded access programs are a partial response to this 
need while real world experience studies may offer a large 
deal of data able to estimate the impact of these novel 
compounds in a population of nccRCC patients.
Cabozantinib is a tyrosine kinase inhibitor able to 
interfere with several altered pathways including: MET, 
AXL, VEGFR 2 and RET (9-13). In ccRCC it has been 
compared to everolimus in patients progressed to standard 
angiogenesis inhibitors (METEOR). In this population 
administration of cabozantinib leads to improved overall 
survival (21.4 versus 16.5 months; HR 0.66, 95% CI: 0.53–
0.83), progression free survival (HR 0.51, 95% CI: 0.41– 
0.62) and objective response rate (17% vs. 3%) compared 
to everolimus (10,11). A randomized phase II studies 
(CABOSUN) has also compared cabozantinib to sunitinib 
in patients with intermediate or poor risk according to 
Table 2 Ongoing phase III and phase II studies on nccRCC
Study ID Arm A Arm B Inclusion Criteria Primary outcome Other outcomes
NCT03091192 (SAVOIR), phase III Savolitinib Sunitinib MET driven pRCC PFS OS/ORR
NCT02761057 (PAPMET), phase II Cabozantinib Sunitinib; Savolitinib; 
Crizotinib
pRCC PFS OS/ORR
NCT03354884 (BONSAI), phase II Cabozantinib – CDC ORR PFS/OS
NCT03075423 
(SUNNIFORECAST), phase II
Nivolumab, 
Ipilimumab
Sunitinib nccRCC 12 months OS PFS/ORR/OS
NCT02724878, phase II Atezolizumab, 
Bevacizumab
– nccRCC ORR PFS/OS
NCT02915783, phase II Everolimus, 
Lenvatinib
– nccRCC ORR PFS/OS
NCT02819596 (CALYPSO),  
phase II
Savolitinib, 
Durvalumab, 
Tremelimumab
– nccRCC, ccRCC Safety/ORR PFS/OS
NCT03635892, phase II Cabozantinib, 
Nivolumab
– nccRCC ORR PFS/OS
nccRCC, non-clear cell renal cell carcinoma; pRCC, papillary renal cell carcinoma; MET, mesenchymal-epithelial transition receptor; CDC, 
collecting duct carcinoma; ORR, objective response rate; PFS, progression free survival; OS, overall survival.
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IMDC criteria. Also in this population cabozantinib 
resulted in improved progression free survival (8.6 versus 
5.3 months, HR 0.48, 95% CI: 0.31–0.74) and response rate 
(20% versus 9%) while no overall survival benefit emerged 
from this study (12,13).
Nowadays, cabozantinib is a recognized and effective 
treatment largely adopted in clinical practice and has 
shown clinical efficacy in patients who previously 
received immunotherapy (monotherapy), immunotherapy 
combination or angiogenesis inhibitors. 
About nccRCC, evidences about the efficacy profiles 
of cabozantinib have been recently provided by Martínez 
Chanzá et al. Authors carried out a retrospective analysis 
of 112 nccRCC patients who received cabozantinib as first 
(20%), second (28%) or more advanced line (53%). The 
majority of tumours were pRCC (59%), TRCC (15%), 
ChRCC (9%), CDC (4%) and unclassified histology 
(13%). Treatment with cabozantinib was associated to a 
median progression free survival and overall survival of 
7.0 (1.7–9.0 months) and 12.0 (9.2–17.2) months 
respectively. Overall 30 of 112 patients (27%, 95% CI: 
19–36) achieved a RECIST response, while 47% achieved a 
stable disease as best response (14).
Of note response to treatment was observed regardless 
previous treatment received, bone metastases, Heng 
prognostic risk, histology (only unclassified RCC 
achieved a lowest rate of objective response: 13%) and 
presence of sarcomatoid features. Curiously, despite no 
difference in objective response rate have been observed 
in patients with/without sarcomatoid features, patients 
presenting sarcomatoid seems to show a lowest time 
of treatment failure (5.1, 95% CI: 2.8–6.2 versus 7.4, 
95% CI: 4.6–11.0 months) and 12 months overall survival 
(25%, 95% CI: 8–47 versus 48%, 95% CI: 31–64). Of 
note, information about genomic assessment was obtained 
in 54 of 112 patients. CDKN2A was the most frequent 
alteration (22%) followed by MET (20%), TP53 (11%), 
FH (9%), SETD2, PTEN and NF2 (7% each one) (14). 
Response to treatment seemed to be not influenced by 
CDKN2A alteration while expression of MET resulted in 
higher response rate (4 of 10 patients with MET alteration 
achieved objective response, 40%) (14). 
This study is for sure the largest evaluation of 
cabozantinib in nccRCC population and confirmed previous 
real-world data evaluating the use of cabozantinib in smaller 
population of nccRCC (15-19).
The inclusion of cabozantinib in clinical practice for 
this specific population is of particular importance as very 
few treatments are available for these patients. Sunitinib, 
temsirolimus and everolimus are the more evaluated 
compounds in nccRCC (Table 1). However, their clinical 
activity is modest in this population. 
Immunotherapy, represented by immune-checkpoint 
inhibitors is another promising treatment strategy for 
patients with metastatic nccRCC. Two studies evaluated 
the impact of immunotherapy in small series of nccRCC 
(41 and 42 patients) (20,21). In these studies, Nivolumab 
was associated to an objective response rate of 19–20% 
and an overall survival of 12 months or more (20). Similar 
results have been achieved by a real-world experience 
carried out by De Giorgi et al. (21). In a phase Ia trial 70 
patients with clear cell (n=63) and non clear cell (n=7) 
renal tumour progressed to mTOR and VEGF/VEGFR 
inhibitors received Atezolizumab (anti programmed death 
ligand 1) (22). This trial showed a favourable toxicity profile 
of the PD-L1 inhibitor with an interesting clinical efficacy 
(ORR 15%) especially in patients with poor prognostic 
features (ORR 22% in tumours with sarcomatoid features 
and high Fuhrman and ISUP grade). Among the seven 
patients with non-clear cell tumour (6 with papillary 
histology and 1 with unknown histology) no RECIST 
tumour responses have been observed (only 1 tumour 
response according to irRC) (22).
Cabozantinib may be attractive and effective drugs in 
patients with nccRCC. Nonetheless, more efforts should 
be spent for the detection of treatments able to improve 
survival of these patients.
Although several trials tailored for specific histology 
are currently ongoing other approaches may improve the 
management of nccRCC. 
The development of shared databases as well as the 
development of network among research centres is a 
winning approach, which could partially help to overcome 
the physiological long time required for the results of 
perspective clinical trials.
Furthermore, the development of an upgraded data sets 
may provide reliable data, which may be used as comparator 
population in larger studies aimed to evaluate new 
compounds. This could be a possible approach to overcome 
problems related to the low incidence of these tumours.
Of course, these patients should be referred to reference 
centres and inclusion in clinical trials should be strongly 
encouraged due to the exiguity of demonstrated clinical 
effective treatments. 
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About new compounds under investigation, the 
combination between ipilimumab (an anti-CTLA-4 
inhibitor) and Nivolumab is currently under investigation 
in patients with nccRCC. This randomized phase 
II  t r ia l  comparing the  combinat ion to  suni t in ib 
(SUNNIFORACAST) is currently ongoing and open to all 
patients with nccRCC. A sequential approach (Nivolumab 
as single agent than associated to ipilimumab) is under 
investigation in UNISoN trial.
Also the combination between Atezolizumab and 
Bevacizumab (NCT02724878), lenvatinib everolimus 
(NCT02915783) is currently evaluating these approaches 
in patients with nccRCC. The combination between 
savolitinib and durvalumab is under evaluation in a phase 
I trial evaluating also savolitinib as mono-treatment, 
durvalumab as single treatment and the combination 
between tremelimumab and durvalumab (CALYPSO). The 
association between Cabozantinib and Nivolumab is also 
under evaluation (NCT03635892).
Expanded access programs will also offer the possibility 
to investigate the more recent combination (Avelumab-
Axitinib, Pembrolizumab-Axitinib) in nccRCC patients.
In conclusion, we are assisting to a revolution in the 
management of metastatic renal cell carcinoma (23-25). 
Despite important progresses have been done for the 
molecular characterization and the development of new 
compounds, nccRCC still remains a disease associated to 
poorest outcomes and prognosis compared to ccRCC. 
Cabozantinib may be an important treatment options for 
these patients as it seems be associated to clinical activity 
regardless histology. 
The planning of nccRCC tailored trials is a critical issue 
for the development of new treatments. 
The build of informatics databases, and shared networks 
may be a key step to acquire important data about 
management of these rare tumours. 
Patients with diagnosis of metastatic nccRCC should be 
oriented in reference centres and inclusion in clinical trials 
should be strongly encouraged.
Acknowledgments
None.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare.
References
1. Giles RH, Choueiri TK, Heng DY, et al. 
Recommendations for the Management of Rare Kidney 
Cancers. Eur Urol 2017;72:974-83. 
2. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 
WHO classification of tumours of the urinary system and 
male genital organs—part A: renal, penile, and testicular 
tumours. Eur Urol 2016;70:93-105.
3. Ciccarese C, Di Nunno V, Montironi R, et al. The role 
of precision medicine for the treatment of metastatic 
renal cell carcinoma. Exp Rev Precision Med Drug 
Development 2016;1:369-77. 
4. Cancer Genome Atlas Research Network, Linehan 
WM, Spellman PT, et al. Comprehensive Molecular 
Characterization of Papillary Renal-Cell Carcinoma. N 
Engl J Med 2016;374:135-45.
5. Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer 
Genome Atlas Comprehensive Molecular Characterization 
of Renal Cell Carcinoma. Cell Rep 2018;23:3698.
6. Davis CF, Ricketts CJ, Wang M, et al. The somatic 
genomic landscape of chromophobe renal cell carcinoma. 
Cancer Cell 2014;26:319-30.
7. Albiges L, Flippot R, Rioux-Leclercq N, et al. Non-Clear 
Cell Renal Cell Carcinomas: From Shadow to Light. J 
Clin Oncol 2018:JCO2018792531. [Epub ahead of print]. 
8. Di Nunno V, Gatto L, Fragomeno B, et al. Combination 
immunotherapy in metastatic renal cell carcinoma. Are we 
leaving something back? Future Oncol 2018;14:2997-9. 
9. Di Nunno V, Cubelli M, Massari F. The role of the MET/
AXL pathway as a new target for multikinase inhibitors 
in renal cell carcinoma. Exp Rev Precision Med Drug 
Development 2017;2:169-75. 
10. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib 
versus everolimus in advanced renal cell carcinoma 
(METEOR): final results from a randomised, open-label, 
phase 3 trial. Lancet Oncol 2016;17:917-27. 
11. Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib 
versus sunitinib as initial therapy for metastatic renal cell 
carcinoma of intermediate or poor risk (Alliance A031203 
CABOSUN randomised trial): Progression-free survival 
by independent review and overall survival update. Eur J 
Cancer 2018; 94:115-25. 
12. Motzer RJ, Escudier B, Powles T. Long-term follow-
up of overall survival for cabozantinib versus everolimus 
in advanced renal cell carcinoma. Br J Cancer 
2018;118:1176-8. 
13. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib 
Di Nunno et al. Cabozantinib for patients with metastatic nccRCC 
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2019;7(Suppl 3):S137 | http://dx.doi.org/10.21037/atm.2019.06.06
Page 6 of 6
Versus Sunitinib As Initial Targeted Therapy for Patients 
With Metastatic Renal Cell Carcinoma of Poor or 
Intermediate Risk: The Alliance A031203 CABOSUN 
Trial. J Clin Oncol 2017;35:591-7. 
14. Martínez Chanzá N, Xie W, Asim Bilen M, et al. 
Cabozantinib in advanced non-clear-cell renal cell 
carcinoma: a multicentre, retrospective, cohort study. 
Lancet Oncol 2019;20:581-90. 
15. Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib 
for the treatment of patients with metastatic non-clear cell 
renal cell carcinoma: A retrospective analysis. Eur J Cancer 
2018;104:188-94. 
16. Prisciandaro M, Ratta R, Massari F, et al. Safety and 
Efficacy of Cabozantinib for Metastatic Nonclear Renal 
Cell Carcinoma: Real-world Data From an Italian 
Managed Access Program. Am J Clin Oncol 2019;42:42-5. 
17. Stukalin I, Wells JC, Graham J, et al. Real-world outcomes 
of nivolumab and cabozantinib in metastatic renal cell 
carcinoma: results from the International Metastatic 
Renal Cell Carcinoma Database Consortium. Curr Oncol 
2019;26:e175-9. 
18. Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of 
patients with metastatic clear-cell renal cell carcinoma 
treated with second-line VEGFR-TKI after first-
line immune checkpoint inhibitors. Eur J Cancer 
2019;114:67-75. 
19. Bodnar L, Kopczyńska A, Żołnierek J, et al. Real-world 
Experience of Cabozantinib as Second- or Subsequent 
Line Treatment in Patients With Metastatic Renal Cell 
Carcinoma: Data From the Polish Managed Access Program. 
Clin Genitourin Cancer 2019;17:e556-64. 
20. Koshkin VS, Barata PC, Zhang T, et al. Clinical activity 
of nivolumab in patients with non-clear cell renal cell 
carcinoma. J Immunother Cancer 2018;29;6:9. 
21. De Giorgi U, Cartenì G, Giannarelli D, et al. Safety and 
efficacy of nivolumab for metastatic renal cell carcinoma: 
real-world results from an expanded access programme. 
BJU Int 2019;123:98-105. 
22. McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, 
an Anti-Programmed Death-Ligand 1 Antibody, in 
Metastatic Renal Cell Carcinoma: Long-Term Safety, 
Clinical Activity, and Immune Correlates From a Phase Ia 
Study. J Clin Oncol 2016;34:833-42. 
23. Mollica V, Di Nunno V, Gatto L, et al. Novel Therapeutic 
Approaches and Targets Currently Under Evaluation for 
Renal Cell Carcinoma: Waiting for the Revolution. Clin 
Drug Investig 2019;39:503-19. 
24. Di Nunno V, Cimadamore A, Santoni M, et al. Biological 
issues with cabozantinib in bone metastatic renal cell 
carcinoma and castration-resistant prostate cancer. Future 
Oncol 2018;14:2559-64. 
25. Santoni M, Massari F, Di Nunno V, et al. Immunotherapy 
in renal cell carcinoma: latest evidence and clinical 
implications. Drugs Context 2018;7:212528. 
Cite this article as: Di Nunno V, Massari F, Mollica V, 
Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, 
Scarpelli M, Montironi R. Another one in the chamber: 
cabozantinib for patients with metastatic non clear cell renal cell 
carcinoma. Ann Transl Med 2019;7(Suppl 3):S137. doi: 10.21037/
atm.2019.06.06
